In this Expert Perspective, Joel Mathews (Ionis Pharmaceuticals Inc., CA, USA) discusses his role in the development of biomarker, PK and immunogenicity assays for protein therapeutics. He explains his research background and interest in the field as well as exploring the use of ligand binding assays (LBA) for biomarker validation.
About the author:
Joel Mathews leads the biomarker group at Ionis Pharmaceuticals Inc., CA, USA where he helps develop biomarkers, PK and immunogenicity assays in the development of protein therapeutics.
Video originally published on Bioanalysis Zone, a digital platform from the Future Science Group that aims to advance the field of bioanalysis by increasing subject understanding and sharing of knowledge across barriers to unite the bioanalytical community.